{"id":866209,"date":"2025-07-02T12:54:12","date_gmt":"2025-07-02T16:54:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/"},"modified":"2025-07-02T12:54:12","modified_gmt":"2025-07-02T16:54:12","slug":"investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/","title":{"rendered":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, July  02, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p9woswXZf8vmJq_DwQ5OcLRgSWoOlpje-NjLuO4ext1F-A3CUdllPRhONB04fHozYXrcJcnsX0T_AxB3ohr4B-vUtJmzIz7Ju3mGP91D9K-s_tM9oOEegVEkpFT_LTVNXk6FMzS0CdWOZFYY01WFKU_l2SJcrPh8pIfuGJfsUxtyLwMFzVLbjV9gYLSzL05H\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a> announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired <strong>Sarepta Therapeutics, Inc.<\/strong> (\u201cSarepta\u201d or the \u201cCompany\u201d) (NASDAQ: SRPT) securities between <strong>June 22, 2023 and June 24, 2025<\/strong>, inclusive (the \u201cClass Period\u201d).<\/p>\n<p>\n        <strong>Investors who purchased or otherwise acquired shares of Sarepta should contact the <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=53XLwSM_V9iGvew2EToNMUBX3QRqWiwPjYJssHASH-_vp-qJitW_FAjr1r11zSeVSQxnPGV1thd8Dnhh9ak4ykB-260TRSvAu-3vY0kun3IWtebulfHPzdtXu50IZ01r\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Firm<\/strong><br \/>\n        <\/a><br \/>\n        <strong> prior to the August 25, 2025 lead plaintiff motion deadline.<\/strong>\n      <\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z11IT2nntQm2fQxIp_TYy0QPPXTIQjD7w1OvEdT3L1k8K5LEkKD7fWWdIMV0xjUkz0CSPXaKasfy7YIN3Af7Ys6Qp6f0ZsEw9DSKgQTa-z16ic0YA6rtGqB-BmJImCpmKXxRAByfl45CHCZ7-q5UqAFWh4QTo0ImbbN76Aof2Gid_JkuRu6glNupWmTPMCCyaKBVAvwec_-_4sM4vbBdpw==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Allegations in the Complaint<\/strong>\n      <\/p>\n<p align=\"justify\">Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product <strong>ELEVIDYS<\/strong>, developed for the treatment of Duchenne muscular dystrophy. According to the filed complaint, during the Class Period, Defendants made false and misleading statements concerning the safety profile, clinical development, and commercial prospects of ELEVIDYS.<\/p>\n<p align=\"justify\">It is alleged that Sarepta:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Misrepresented the safety of ELEVIDYS, despite serious risks;<\/li>\n<li style=\"margin-bottom:8pt\">Failed to detect or disclose severe adverse events during clinical trials;<\/li>\n<li style=\"margin-bottom:8pt\">Withheld material information that eventually led to halted dosing, increased regulatory scrutiny, and suspension of shipments;<\/li>\n<li style=\"margin-bottom:8pt\">Lacked a reasonable basis for positive statements about ELEVIDYS\u2019s safety and potential for expanded use.<\/li>\n<\/ul>\n<p>\n        <strong>Key Events and Stock Impact<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>March 18, 2025<\/strong>: <a href=\"https:\/\/www.cgtlive.com\/view\/patient-dies-acute-liver-failure-treatment-sarepta-dmd-gene-therapy-elevidys\" rel=\"nofollow\" target=\"_blank\">Sarepta disclosed the death of a patient treated with ELEVIDYS.<\/a> Shares dropped <strong>27.44%<\/strong>, closing at <strong>$73.54<\/strong>.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>April 4, 2025<\/strong>: Sarepta halted certain clinical studies after European regulators called for a safety review. Shares fell <strong>7.13%<\/strong>, closing at <strong>$54.43<\/strong>.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>June 15, 2025<\/strong>: <a href=\"https:\/\/www.biopharmadive.com\/news\/sarepta-elevidys-duchenne-gene-therapy-death-second\/750752\/\" rel=\"nofollow\" target=\"_blank\">A second patient death due to acute liver failure was announced<\/a>, along with shipment suspensions. Shares plummeted <strong>42.12%<\/strong>, closing at <strong>$20.91<\/strong>.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>June 24, 2025<\/strong>: <a href=\"https:\/\/www.cgtlive.com\/view\/fda-announces-investigation-deaths-following-treatment-sarepta-dmd-gene-therapy-elevidys\" rel=\"nofollow\" target=\"_blank\">The FDA issued a safety communication regarding the deaths<\/a>. Shares declined another <strong>8.01%<\/strong>, closing at <strong>$17.46<\/strong> on June 25, 2025.<\/li>\n<\/ul>\n<p>\n        <strong>Investor Action Deadline<\/strong>\n      <\/p>\n<p>If you purchased Sarepta securities during the Class Period and suffered losses, you have until <strong>August 25, 2025<\/strong>, to request the Court appoint you as lead plaintiff.<\/p>\n<p>\n        <strong>Why\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p9woswXZf8vmJq_DwQ5OcLRgSWoOlpje-NjLuO4ext1F-A3CUdllPRhONB04fHozdq3p0VcAV_qCBR1plNXf2QxKoTq40wLNf6XxKAkATeLxfgt1d48wxJ3FyRwxNQhu37j2su-hUoJ6rTUxeDxbF29vrMUmRAYkOhbIDnRoPTcJtlHWvQdT2u09CP-8NqCU\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/u><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong>?<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p align=\"justify\">This illustrious<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x4uq08NjATX9l35AY463nUDpf8SfzFNKoX-NHZaMZpKGBSVpGoNeQlRjYyuBALvXa78biiYQvYDisDa024haSnNfk3hMPeKA34LViyQZ98o79Uhi7TDgbUuBgmbxLfmB-PgjUD-Qmwp8en6U70_MxA==\" rel=\"nofollow\" target=\"_blank\"> firm,<\/a> founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DCVla5kvzsuS64EvMETdlI4m4bi1qzIAJLYTC6Zwb1n6KW4oV_0ohDDoCeRpmdv9ar3nRllUN-mZXrzEu3xamiGTO6n1xhc757DdqSmBaoo0izMz4cWeETempTLeGmNQidtv02to2Ilk_x0j228Qeg==\" rel=\"nofollow\" target=\"_blank\">law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n<p align=\"justify\">We encourage all investors who have been suffered losses or have information that will assist in our investigation, to contact\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p9woswXZf8vmJq_DwQ5OcLRgSWoOlpje-NjLuO4ext1F-A3CUdllPRhONB04fHozqedrmZgwOM3eXW3xGwk5bcSXiUPSP1TBCFpWxQU0HQJjwahvuTO5jxQq7YeLLJrwaSQD2v1bOH41HTZs28zZj1_Hy8Sgu5QvIltc2m1w9uj7glvX3gn6XayLNkNJtND0\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP.<\/a><\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Phone:<\/strong>\u00a0(800) 575-0735 or (212) 545-4774<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Email:\u00a0<\/strong><br \/>\n          <a href=\"mailto:classmember@whafh.com\" rel=\"nofollow\" target=\"_blank\">classmember@whafh.com<\/a>\n        <\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Contact Person:<\/strong>\u00a0<a href=\"mailto:gstone@whafh.com\" rel=\"nofollow\" target=\"_blank\">Gregory Stone, Director of Case and Financial Analysis<\/a><\/li>\n<\/ul>\n<p>\n        <strong>Firm Website:<\/strong>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p9woswXZf8vmJq_DwQ5OcLRgSWoOlpje-NjLuO4ext1F-A3CUdllPRhONB04fHoz0EabyTEStyIApcrYzeFLK7cLLjgEox2Igy6z540eSo7-tdNemCPd-ymjwpqIVhvyVy_-3Xy5mPmu7mzZIlmeawKL90EtZpXKJJbI1sYNhZTt8Ko1HDYLD4nvo8ImxTOU\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a><\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTAxMWI2NTUtYWMyOS00NmFkLWFjMmMtOWI1ZWNhYmVkZjA3LTEwMjkyNDItMjAyNS0wNy0wMi1lbg==\/tiny\/Wolf-Haldenstein-Adler-Freeman.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (\u201cSarepta\u201d or the \u201cCompany\u201d) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the \u201cClass Period\u201d). Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm prior to the August 25, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations in the Complaint Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product ELEVIDYS, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866209","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (\u201cSarepta\u201d or the \u201cCompany\u201d) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the \u201cClass Period\u201d). Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm prior to the August 25, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations in the Complaint Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product ELEVIDYS, &hellip; Continue reading &quot;INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-02T16:54:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)\",\"datePublished\":\"2025-07-02T16:54:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/\"},\"wordCount\":452,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/\",\"name\":\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=\",\"datePublished\":\"2025-07-02T16:54:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk","og_description":"NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (\u201cSarepta\u201d or the \u201cCompany\u201d) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the \u201cClass Period\u201d). Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm prior to the August 25, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations in the Complaint Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product ELEVIDYS, &hellip; Continue reading \"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-02T16:54:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)","datePublished":"2025-07-02T16:54:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/"},"wordCount":452,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/","name":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=","datePublished":"2025-07-02T16:54:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODUwOCM3MDMwMDMzIzIwMTc2NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866209"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866209\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}